Here are four things to know.
1. Ogivri is a biosimilar version of Genentech’s cancer drug Herceptin.
2. The drug is intended to treat patients with breast or metastatic stomach cancer.
3. Ogivri is the second biosimilar approved for cancer, and the first approved to treat stomach and breast cancer.
4. Both Ogivri and Herceptin contain a boxed warning over an increased risk of heart disease, infusion reactions, lung damage and harm to fetuses.
More articles on supply chain:
Pfizer to launch generic version of Viagra at $33 per pill
FDA urges drugmaker to recall osteoarthritis product following liver and lung injury reports
Amazon withdraws application for pharmacy license in Maine
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.